Luteal phase support with GnRH-a improves implantation and pregnancy rates in IVF cycles with endometrium of ≤7 mm on day of egg retrieval

Qublan, Hussein S.; Amarin, Zouhair; Al-Quda, M.; Diab, F. M.; Nawasreh, M.; Malkawi, S.; Balawneh, M.

doi:10.1080/14647270701704768

Cited by 49 publications

(33 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the basis of these data, it may seem attractive to consider administration of a single dose of GnRH-a in the IVF/ICSI luteal phase to improve clinical outcomes, especially in GnRH antagonist cycles. Other RCTs not included in this meta-analysis [19,20] yielded the same results. Although these trials were performed in different conditions (GnRH agonist administration was continued until 14 days after oocyte retrieval; GnRH agonist administration on the day of ovum pickup, on the day of embryo transfer and three days thereafter, respectively), their outcomes are clearly consistent with those of this meta-analysis (i.e.…”

Section: Discussionsupporting

confidence: 55%

Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis

Oliveira

Baruffi

Petersen

et al. 2010

Reprod Biol Endocrinol

View full text Add to dashboard Cite

BackgroundThe effects of gonadotrophin-releasing hormone agonist (GnRH-a) administered in the luteal phase remains controversial. This meta-analysis aimed to evaluate the effect of the administration of a single-dose of GnRH-a in the luteal phase on ICSI clinical outcomes.MethodsThe research strategy included the online search of databases. Only randomized studies were included. The outcomes analyzed were implantation rate, clinical pregnancy rate (CPR) per transfer and ongoing pregnancy rate. The fixed effects model was used for odds ratio. In all trials, a single dose of GnRH-a was administered at day 5/6 after ICSI procedures.ResultsAll cycles presented statistically significantly higher rates of implantation (P < 0.0001), CPR per transfer (P = 0.006) and ongoing pregnancy (P = 0.02) in the group that received luteal-phase GnRH-a administration than in the control group (without luteal-phase-GnRH-a administration). When meta-analysis was carried out only in trials that had used long GnRH-a ovarian stimulation protocol, CPR per transfer (P = 0.06) and ongoing pregnancy (P = 0.23) rates were not significantly different between the groups, but implantation rate was significant higher (P = 0.02) in the group that received luteal-phase-GnRH-a administration. On the other hand, the results from trials that had used GnRH antagonist multi-dose ovarian stimulation protocol showed statistically significantly higher implantation (P = 0.0002), CPR per transfer (P = 0.04) and ongoing pregnancy rate (P = 0.04) in the luteal-phase-GnRH-a administration group. The majority of the results presented heterogeneity.ConclusionsThese findings demonstrate that the luteal-phase single-dose GnRH-a administration can increase implantation rate in all cycles and CPR per transfer and ongoing pregnancy rate in cycles with GnRH antagonist ovarian stimulation protocol. Nevertheless, by considering the heterogeneity between the trials, it seems premature to recommend the use of GnRH-a in the luteal phase. Additional randomized controlled trials are necessary before evidence-based recommendations can be provided.

show abstract

Section: Discussionsupporting

confidence: 55%

Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis

Oliveira

Baruffi

Petersen

et al. 2010

Reprod Biol Endocrinol

View full text Add to dashboard Cite

show abstract

“…Similarly, Ata et al (21), using the same study design as Tesarik et al (18), i.e., a randomly single-dose administration of 0.1 mg of triptorelin versus placebo 6 days after ICSI in women stimulated with a long GnRH agonist protocol, with almost double the sample size (n ¼ 570) as Tesarik et al (n ¼ 300) (18), did not find differences in implantation, clinical pregnancy, and multiple pregnancy rates. Nevertheless, other isolated reports have suggested a beneficial effect of GnRH agonist administration in IVF during the luteal phase in some specific situations, such as a thin endometrium (48), or at other stages of ovarian stimulation (e.g., together with hCG administration before oocyte pick-up in GnRH antagonist cycles) (49), but without confirmation.…”

Section: Discussionmentioning

confidence: 97%

GnRH agonist administration at the time of implantation does not improve pregnancy outcome in intrauterine insemination cycles: a randomized controlled trial

Bellver

Labarta

Bosch

et al. 2010

Fertility and Sterility

View full text Add to dashboard Cite

“…Celle-ci se poursuivait à j6 pour la LH et la FSH. Cet effet flare-up est é galement retrouvé dans les é tudes de Tesarik et de Qublan [20,22].…”

Section: Discussionunclassified

Administration d’agonistes de la GnRH (Gonadotrophin Releasing Hormone) en phase lutéale des protocoles substitutifs de transferts d’embryons congelés : étude prospective randomisée

Gogce

Benchaïb

Hadj

et al. 2015

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

Luteal phase support with GnRH-a improves implantation and pregnancy rates in IVF cycles with endometrium of ≤7 mm on day of egg retrieval

Abstract: The administration of GnRH-a at the time of OPU significantly improves the implantation and pregnancy rates in patients with thin endometrium (

Cited by 49 publications

References 20 publications

Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis

Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis

GnRH agonist administration at the time of implantation does not improve pregnancy outcome in intrauterine insemination cycles: a randomized controlled trial

Administration d’agonistes de la GnRH (Gonadotrophin Releasing Hormone) en phase lutéale des protocoles substitutifs de transferts d’embryons congelés : étude prospective randomisée

Contact Info

Product

Resources

About